SONORX
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SONORX is an oral suspension NDA approved by the FDA in October 1998 and currently marketed by Bracco. The mechanism of action and specific indications are not publicly detailed in available data, limiting clinical characterization.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should expect market erosion and resource reallocation toward next-generation assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SONORX currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Career growth on this product is limited; professionals should consider transitions to growth-stage assets within the Bracco portfolio or external opportunities.
Brand ManagerField Sales Representative
Worked on SONORX at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.